PortalPublikationenEffect of statin use on outcomes of non-muscle-invasive blad...

Effect of statin use on outcomes of non-muscle-invasive bladder cancer

Standard

Effect of statin use on outcomes of non-muscle-invasive bladder cancer. / Crivelli, Joseph J; Xylinas, Evanguelos; Kluth, Luis A; da Silva, Rodrigo Donalisio; Chrystal, James; Novara, Giacomo; Karakiewicz, Pierre I; David, Scott G; Scherr, Douglas S; Lotan, Yair; Shariat, Shahrokh F.

in: BJU INT, Jahrgang 112, Nr. 2, 01.07.2013, S. E4-12.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Crivelli, JJ, Xylinas, E, Kluth, LA, da Silva, RD, Chrystal, J, Novara, G, Karakiewicz, PI, David, SG, Scherr, DS, Lotan, Y & Shariat, SF 2013, 'Effect of statin use on outcomes of non-muscle-invasive bladder cancer', BJU INT, Jg. 112, Nr. 2, S. E4-12. https://doi.org/10.1111/bju.12150

APA

Crivelli, J. J., Xylinas, E., Kluth, L. A., da Silva, R. D., Chrystal, J., Novara, G., Karakiewicz, P. I., David, S. G., Scherr, D. S., Lotan, Y., & Shariat, S. F. (2013). Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU INT, 112(2), E4-12. https://doi.org/10.1111/bju.12150

Vancouver

Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU INT. 2013 Jul 1;112(2):E4-12. https://doi.org/10.1111/bju.12150

Bibtex

@article{1d95587e892c4ba8961cdfa765e0bfe5,
title = "Effect of statin use on outcomes of non-muscle-invasive bladder cancer",
abstract = "OBJECTIVES: To assess the impact of statin use on outcomes of patients with non-muscle-invasive bladder cancer (NMIBC). To measure the effect of statin use on the efficacy of intravesical bacillus Calmette-Gu{\'e}rin (BCG) therapy.PATIENTS AND METHODS: A retrospective analysis was performed on 1117 patients treated with transurethral resection of the bladder (TURB) for NMIBC at three institutions between 1996 and 2007. Statin use at the time of diagnosis was recorded for each patient. Univariable Cox regression models addressed the association of statin use with disease recurrence, disease progression, cancer-specific mortality and overall mortality in all patients, patients with primary NMIBC, patients not treated with BCG, and patients treated with BCG.RESULTS: Overall, 341 patients (30.5%) used statins and 776 (69.5%) did not. Within a median (interquartile range) follow-up of 62.7 (25.0-110.7) months, 469 patients (42.0%) experienced disease recurrence, 103 (9.2%) progression, 50 (4.5%) cancer-specific mortality, and 299 (26.8%) any-cause mortality. In univariable Cox regression analyses, statin use was not associated with any of these four endpoints (P > 0.05 for all). In subgroup analyses, statin use was also not associated with prognosis in patients with primary NMIBC or patients not receiving BCG (P > 0.05 for all four endpoints). Statin use was not associated with response to BCG (P > 0.05 for all four endpoints).CONCLUSION: Statin users did not experience different outcomes compared with non-users and statin use did not affect the efficacy of BCG immunotherapy; these data do not support modification or discontinuation of statin therapy for patients with NMIBC.",
keywords = "Aged, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Neoplasm Invasiveness, Retrospective Studies, Treatment Outcome, Urinary Bladder Neoplasms",
author = "Crivelli, {Joseph J} and Evanguelos Xylinas and Kluth, {Luis A} and {da Silva}, {Rodrigo Donalisio} and James Chrystal and Giacomo Novara and Karakiewicz, {Pierre I} and David, {Scott G} and Scherr, {Douglas S} and Yair Lotan and Shariat, {Shahrokh F}",
note = "{\textcopyright} 2013 BJU International.",
year = "2013",
month = jul,
day = "1",
doi = "10.1111/bju.12150",
language = "English",
volume = "112",
pages = "E4--12",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Effect of statin use on outcomes of non-muscle-invasive bladder cancer

AU - Crivelli, Joseph J

AU - Xylinas, Evanguelos

AU - Kluth, Luis A

AU - da Silva, Rodrigo Donalisio

AU - Chrystal, James

AU - Novara, Giacomo

AU - Karakiewicz, Pierre I

AU - David, Scott G

AU - Scherr, Douglas S

AU - Lotan, Yair

AU - Shariat, Shahrokh F

N1 - © 2013 BJU International.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - OBJECTIVES: To assess the impact of statin use on outcomes of patients with non-muscle-invasive bladder cancer (NMIBC). To measure the effect of statin use on the efficacy of intravesical bacillus Calmette-Guérin (BCG) therapy.PATIENTS AND METHODS: A retrospective analysis was performed on 1117 patients treated with transurethral resection of the bladder (TURB) for NMIBC at three institutions between 1996 and 2007. Statin use at the time of diagnosis was recorded for each patient. Univariable Cox regression models addressed the association of statin use with disease recurrence, disease progression, cancer-specific mortality and overall mortality in all patients, patients with primary NMIBC, patients not treated with BCG, and patients treated with BCG.RESULTS: Overall, 341 patients (30.5%) used statins and 776 (69.5%) did not. Within a median (interquartile range) follow-up of 62.7 (25.0-110.7) months, 469 patients (42.0%) experienced disease recurrence, 103 (9.2%) progression, 50 (4.5%) cancer-specific mortality, and 299 (26.8%) any-cause mortality. In univariable Cox regression analyses, statin use was not associated with any of these four endpoints (P > 0.05 for all). In subgroup analyses, statin use was also not associated with prognosis in patients with primary NMIBC or patients not receiving BCG (P > 0.05 for all four endpoints). Statin use was not associated with response to BCG (P > 0.05 for all four endpoints).CONCLUSION: Statin users did not experience different outcomes compared with non-users and statin use did not affect the efficacy of BCG immunotherapy; these data do not support modification or discontinuation of statin therapy for patients with NMIBC.

AB - OBJECTIVES: To assess the impact of statin use on outcomes of patients with non-muscle-invasive bladder cancer (NMIBC). To measure the effect of statin use on the efficacy of intravesical bacillus Calmette-Guérin (BCG) therapy.PATIENTS AND METHODS: A retrospective analysis was performed on 1117 patients treated with transurethral resection of the bladder (TURB) for NMIBC at three institutions between 1996 and 2007. Statin use at the time of diagnosis was recorded for each patient. Univariable Cox regression models addressed the association of statin use with disease recurrence, disease progression, cancer-specific mortality and overall mortality in all patients, patients with primary NMIBC, patients not treated with BCG, and patients treated with BCG.RESULTS: Overall, 341 patients (30.5%) used statins and 776 (69.5%) did not. Within a median (interquartile range) follow-up of 62.7 (25.0-110.7) months, 469 patients (42.0%) experienced disease recurrence, 103 (9.2%) progression, 50 (4.5%) cancer-specific mortality, and 299 (26.8%) any-cause mortality. In univariable Cox regression analyses, statin use was not associated with any of these four endpoints (P > 0.05 for all). In subgroup analyses, statin use was also not associated with prognosis in patients with primary NMIBC or patients not receiving BCG (P > 0.05 for all four endpoints). Statin use was not associated with response to BCG (P > 0.05 for all four endpoints).CONCLUSION: Statin users did not experience different outcomes compared with non-users and statin use did not affect the efficacy of BCG immunotherapy; these data do not support modification or discontinuation of statin therapy for patients with NMIBC.

KW - Aged

KW - Female

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Middle Aged

KW - Neoplasm Invasiveness

KW - Retrospective Studies

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

U2 - 10.1111/bju.12150

DO - 10.1111/bju.12150

M3 - SCORING: Journal article

C2 - 23795797

VL - 112

SP - E4-12

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 2

ER -